Galderma agrees to buy ZO Skin Health for USD 1.5 billion

Galderma agreed to buy physician-dispensed skincare brand ZO Skin Health for an enterprise value of USD 1.5 billion in cash. Deal expected to close in Q4 2026 or early 2027, subject to customary closing conditions. ZO Skin Health recorded about USD 330 million net sales in the 12 months ended June 2026. Purchase to be funded with existing cash and bank financing; 2027 Core EBITDA margin seen slightly dilutive. Core EPS expected neutral in the first full year post-close; margin targeted broadly in line with group average from 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galderma Group AG published the original content used to generate this news brief via (Ref. ID: 20261013945338) on October 14, 2026, and is solely responsible for the information contained therein. (C)